atkins: pembrolizumab, ipilimumab for melanoma, rcc
Published 9 years ago • 101 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
2:24
combination pembrolizumab and reduced-dose ipilimumab: how low can you go?
-
1:24
dr. atkins on adjuvant ipilimumab in melanoma
-
3:35
keynote-006: the efficacy of ipilimumab after pembrolizumab in patients with advanced melanoma
-
5:44
hcrn-gu16-260: nivolumab and salvage nivolumab-ipilimumab in patients with advanced rcc
-
2:34
keynote-029: pembrolizumab with ipilimumab for melanoma
-
7:34
adjuvant therapy for melanoma: nivolumab, pembrolizumab, ipilimumab, dabrafenib and trametinib
-
2:35
dr. atkins on long-term survival benefit of nivolumab/ipilimumab in advanced melanoma
-
24:18
pembrolizumab is better than ipilimumab for advanced melanoma in phase iii trial
-
6:16
treatment-free survival results of nivolumab and salvage nivolumab ipilimumab for accrcc
-
8:26
front-line therapy with nivolumab and salvage nivolumab ipilimumab in patients with advanced rcc
-
47:20
melanoma immunotherapy: what's next for patients? with antoni ribas
-
2:01
michael atkins, md, discusses checkmate-214 investigating nivolumab ipilimumab in rcc patients
-
0:37
tils prolong pfs compared with pembrolizumab in advanced melanoma
-
2:16
the agents at the forefront of kidney cancer treatment
-
0:59
specific patient populations benefit from nivolumab/ipilimumab combo therapy
-
5:37
phase iii trial shows pembrolizumab preferable to ipilimumab in advanced melanoma
-
10:19
ipilimumab alone or in combination w anti-pd-1 therapy in pts w melanoma resistant to anti-pd1 mono
-
1:26
longterm benefits from nivolumab and ipilimumab combination therapy
-
2:22
melanoma treatment: nivolumab (opdivo) vs. pembrolizumab (keytruda) | memorial sloan kettering